Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glial cell line-derived neurotrophic factor variant
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Implant
01
Overview
The **glial cell line-derived neurotrophic factor variant** was an unnamed, biosynthetically engineered recombinant GDNF biologic developed by Eli Lilly in a 2011 early-stage collaboration with Medtronic for Parkinson's disease. The variant was designed to improve distribution within targeted brain regions relative to prior GDNF approaches. It was intended for continuous, targeted intracerebral administration using Medtronic's implantable infusion system, comprising a drug pump and specialized catheter, to bypass the blood-brain barrier. GDNF signaling is mediated through the GFRα1 co-receptor and RET receptor tyrosine kinase, supporting neuronal survival and potentially protecting dopaminergic neurons affected in Parkinson's disease.
- Other names
- glial cell derived neurotrophic factor variantmodified form of glial cell derived neurotrophic factormodified glial cell-derived neurotrophic factornovel GDNF variant
02
Targets
GFRα1 (Glial cell line-derived neurotrophic factor receptor alpha 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on glial cell line-derived neurotrophic factor variant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glial cell line-derived neurotrophic factor variant.